PIK3CA and Hyperglycemia: All patients should be provided with a glucometer and advised to measure fasting BGL and 2-h post-dinner BGL levels twice per week for at least the first 30 days of treatment with a PI3K inhibitor, as PI3K inhibitor-associated hyperglycemia tends to occur early in the treatment course; the median time of onset for hyperglycemia was 15 days in the SOLAR-1 trial (7).